Drug Trial Radar · NCT06045754
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 18, 2024
Primary completion
Jun 28, 2027
Study completion Jun 28, 2027
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A. Each participant will be followed up for at least 26 weeks after the last dose of treatment.
Conditions
- Crohn's Disease
Interventions
VedolizumabDrug
Vedolizumab intravenous infusion.
AdalimumabDrug
Adalimumab subcutaneous injection.
UstekinumabDrug
Ustekinumab intravenous infusion.
UstekinumabDrug
Ustekinumab subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants With an Endoscopic Response Based on the Simple Endoscopic Score for (SES-CD) at Week 26Time frame: At Week 26
- Part B: Percentage of Participants With an Endoscopic Response Based on the SES-CD at Week 52Time frame: At Week 52
Locations
48 sites in 2 countries. Site status is shown where the registry gives one.
Digestive Health Specialsits
Dothan, Alabama
GI Alliance Sun City
Sun City, Arizona
University of California San Diego Health (UCSD)
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
Hoag Hospital Newport Beach
Newport Beach, California
Medical Research Center of Connecticut, LLC
Hamden, Connecticut
Clinical Research of Osceola
Kissimmee, Florida
Endoscopic Research Inc
Orlando, Florida
Alliance Clinical Research of Tampa, LLC
Tampa, Florida
Gastroenterology Consultants, P.C.
Roswell, Georgia
University of Chicago Medicine
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Cotton ONeil Clinical Research Center
Topeka, Kansas
University of Louisville
Louisville, Kentucky
GI Alliance
Metairie, Louisiana
Tulane University
New Orleans, Louisiana
Huron Gastroenterology Associates, P.C.
Ypsilanti, Michigan
Mid-America Gastro-Intestinal Consultants
Kansas City, Missouri
BVL Clinical Research
Liberty, Missouri
Washington University School of Medicine
St Louis, Missouri
NYU Langone Health
New York, New York
University of Cincinnati
Cincinnati, Ohio
Ohio Gastroenterology group, Inc.
Columbus, Ohio
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio
Gastro Intestinal Research Institute of Northern Ohio, LLC.
Westlake, Ohio
Digestive Disease Specialists, Inc.
Oklahoma City, Oklahoma
Allegheny Health Network
Wexford, Pennsylvania
University Gastroenterology
Providence, Rhode Island
Sanford Health Research
Rapid City, South Dakota
Texas Digestive Disease Consultants Cedar Park
Cedar Park, Texas
GI Alliance - Digestive Health Associates of Texas
Dallas, Texas
The University of Texas Health Science Center at Houston
Houston, Texas
Texas Digestive Disease Consultants Lubbock
Lubbock, Texas
GI Alliance - Mansfield
Mansfield, Texas
Gastroenterology Research of San Antonio, LLC
San Antonio, Texas
Southern Star Research Institute, LLC.
San Antonio, Texas
Texas Digestive Disease Consultants (TDDC), Southlake
Southlake, Texas
Tyler Research Institute, LLC
Tyler, Texas
GI Alliance - Webster
Webster, Texas
University of Utah Health
Salt Lake City, Utah
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.